Anaphylaxis And COVID-19 Vaccines

A report published in JAMA on February 12, 2021 entitled “Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021” stated: “anaphylaxis following vaccination is a rare event, with rates of 4.7 cases/million Pfizer-BioNTech vaccine doses administered and 2.5 cases/million Moderna vaccine doses administered, based on information through January 18, 2021. When considered in the context of morbidity and mortality from COVID-19, the benefits of vaccination far outweigh the risk of anaphylaxis, which is treatable. Because of the acute, life-threatening nature of anaphylaxis, immediate epinephrine administration is indicated for all cases … All facilities administering COVID-19 vaccines should have the necessary supplies and trained medical personnel available to manage anaphylaxis.”

“In 61 (92%) of the anaphylaxis cases, patients received epinephrine as part of emergency treatment. All 66 persons were treated in health care settings; 34 (52%) were treated in an emergency department and 32 (48%) were hospitalized (including 18 in intensive care, 7 of whom required endotracheal intubation). As determined by medical record review and follow-up with treating health care facilities and clinicians, of the 7 patients who required endotracheal intubation, median time to symptom onset was 6 minutes (range, <1-45 minutes), with all but one patient having onset within 11 minutes. All 7 of those intubated received epinephrine, 6 received corticosteroids, and 5 received antihistamines; facial, tongue, or laryngeal angioedema was present in 4 of these patients; and hospitalization ranged from 1 to 3 days. Sixty-one individuals (92%) with follow-up information available are known to have been discharged from care or had recovered at the time of report to VAERS. No deaths from anaphylaxis after vaccination with either product were reported.”

“[T]here were no apparent clinical differences between anaphylaxis cases with symptom onset within 30 minutes and those with symptom onset after 30 minutes (a 15-minute postvaccination observation period is recommended for all persons and a 30-minute period is recommended for those with a history of certain allergic reactions). Common signs and symptoms in anaphylaxis cases were generalized urticaria, diffuse erythematous rash, angioedema, respiratory and airway obstruction symptoms, and nausea. Twenty-one (32%) of the 66 case reports noted a prior episode of anaphylaxis from other exposures; prior exposures included vaccines (rabies, influenza A[H1N1], seasonal influenza, unspecified), contrast media (gadolinium-based, iodine-based, unspecified intravenous), unspecified infusions, sulfa drugs, penicillin, prochlorperazine, latex, walnuts, unspecified tree nuts, jellyfish stings, and unspecified exposures.”


As of January 10, 2021, a reported 4,041,396 first doses of Moderna COVID-19 vaccine had been administered in the United States, and reports of 1,266 (0.03%) adverse events after receipt of Moderna COVID-19 vaccine were submitted to the Vaccine Adverse Event Reporting System (VAERS). Among these, 108 case reports were identified for further review as possible cases of severe allergic reaction, including anaphylaxis.


If you or a loved one may have been injured by the COVID-19 vaccine in the United States, you should promptly contact a COVID-19 vaccine lawyer who may investigate your COVID-19 medical malpractice claim for you and represent you and/or your loved one in a COVID-19 vaccine case, if appropriate.

Click here to visit our website or call us toll-free in the United States at 800-295-3959 to find COVID-19 attorneys in your U.S. state who may assist you.

Turn to us when you don’t know where to turn.

This entry was posted on Monday, February 15th, 2021 at 5:23 am. Both comments and pings are currently closed.


Easy Free Consultation

Fill out the form below for a free consultation or contact us directly at 800.295.3959.
  • Please enter the correct answer to this math problem.
  • This field is for validation purposes and should be left unchanged.

    Easy Free Consultation

    Fill out the form below for a free consultation or contact us directly at 800.295.3959